Skip to main content
. 2018 Jan 20;36(4):467–475. doi: 10.1007/s40273-018-0610-0

Table 4.

pCODR recommendations by incremental cost-effectiveness ratio

$Can Full approval Conditional approval Rejection All
< $50,000 5 0 2 7
$50–100,000 6 5 2 13
$100–150,000 3 12 5 20
$150–200,000 0 14 8 22
> $200,000 0 23 7 30
Unreported 1 1 0 2
All 15 55 24 94

Chi-squared = 39.63, p < 0.001

ICER incremental cost-effectiveness ratio, pCODR pan-Canadian Oncology Drug Review